Why Kalvista Pharmaceuticals Shares Are Down Over 50%
Kalvista Pharmaceuticals Inc (NASDAQ: KALV) shares are trading lower by 52.42% to $6.78 Tuesday morning after the company announced it terminated the KOMPLETE phase 2 clinical trial for KVD824 for the prevention of attacks in people with hereditary angioedema.
What Else?